Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma, Refractory: early-phase trial registry
4 of 5 indexed Multiple Myeloma, Refractory trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Multiple Myeloma, Refractory: 5 US clinical trials tracked, 4 recruiting.
Multiple Myeloma, Refractory is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Oncotherapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition multiple-myeloma-refractory
OPEN 4 | RECR 80% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Multiple Myeloma, Refractory lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma, Refractory on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma, Refractory is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Multiple Myeloma, Refractory research.
Oncotherapeutics accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Multiple Myeloma, Refractory trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Multiple Myeloma, Refractory research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
NCT06115135
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Luminary Therapeutics
NCT05546723
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Oncotherapeutics
NCT06225310
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Duke University
NCT06822972
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
All4Cure
NCT05673083
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Myeloma, Refractory records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Myeloma, Refractory trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Myeloma, Refractory page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Multiple Myeloma, Refractory trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Oncotherapeutics sponsors the most Multiple Myeloma, Refractory trials on record, review their full trial history before evaluating a specific study. See Oncotherapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Myeloma, Refractory condition card totals 5 registered trials; most-linked intervention Autologous CAR-T cell therapy expressing the BAFF-ligand.; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.